Skip to main content
OpenTrials
Completed

NCT Number: NCT00592917

OSTPRE-Fracture Prevention Study

The purpose of this study is to determine the effect of calcium 1000 mg/d and vitamin-D3 800 IU/d divided in two daily doses on the incidence of falls and fractures, bone mineral density and bone metabolism in postmenopausal women 65-71 years of age.

Completed

Looking for future studies?

Notify Me

Key information

Age range

65 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Phase 4

Primary location

Bone and Cartilage Research Unit, Clinical Research Centre, University of Kuopio

Kuopio, 70211, Finland

About this study

In aging population osteoporotic fractures in postmenopausal women are a growing problem and a cause of remarkable morbidity, individual suffering and costs. The effect of calcium and vitamin-D in fracture prevention have been tested in elderly patients mostly over 70-75 years of age and results with low dose intervention have been controversial. The aim of this study is to determine the effects of calcium (1000 mg/d) and vitamin-D (800 IU/d) in 65-71 year-old postmenopausal women in a clinical trial on two levels: a) a randomized postal interview trial (n=3432) and b) a randomized clinical trial (n=606). 5407 women of the OSTPRE-cohort received a postal enquiry with questions of health related issues and willingness to participate a calcium and vitamin-D survey. 4706 enquiries were returned. 3432 eligible women were randomised to the active treatment group (n=1718) to receive the intervention and control group (n=1714), that did not receive placebo, they were told to go on as before in terms of calcium or vitamin-D substitution. On the level of the interview trial end point variables, falls and fractures, are collected by telephone interviews annually and on the level of the clinical trial every four months. In clinically examined subset of 606 subjects axial and heel bone mineral density (BMD), heel quantitative ultrasound (QUS) measurement, anthropometric measurements, a comprehensive set of clinical (muscle strength, balance, functional capacity) and laboratory tests (serum calcium, phosphate, AFOS, creatinine, cholesterol, triglycerides, complete blood count, 25-OH-D-vitamin, PTH, osteocalcin and Trap5B and reserve, serum and urine samples) will be performed and food diary will be obtained at baseline and after 3 years follow-up and baseline blood samples will be taken for DNA-analyses.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Alive member of the original population based sample (n=14220) of Kuopio Osteoporosis Risk factor and Prevention Study
  • Age 65 years or older on 30.11.2002
  • Not participating any previous BMD-measurement in OSTPRE
  • Living in the province of Kuopio
  • Adequately filled baseline enquiry
  • Willing to participate calcium and vitamin-D -survey

Treatment and study plan

calcium carbonate and cholecalciferol

Dietary Supplement

one tablet (calcium carbonate resembling 500 mg of calcium and 400 IU or 5 micrograms of vitamin-D3, cholecalciferol) twice daily for the whole duration of the study

Other names: Calcichew D3 forte (Leiras-Nycomed), ATC-code: A12AX

Primary outcomes

  1. fractures

    Time frame: 3 year follow-up

Secondary outcomes

  1. falls

    Time frame: 3 year follow-up

  2. bone mineral density measured by axial DXA, heel pDXA, heel QUS and distal forearm pQCT

    Time frame: 3 year follow-up

  3. markers of bone metabolism

    Time frame: 3 year follow-up

  4. serum vitamin-D levels

    Time frame: 3 year follow-up

  5. serum calcium levels

    Time frame: 3 year follow-up

Sponsors and collaborators

Lead sponsor

Kuopio University Hospital

Other

Collaborators

  • Academy of Finland
  • Leiras-Nycomed
  • University of Eastern Finland

Registry information

Official study title

OSTPRE-FPS Prevention of Fractures and Falls in Postmenopausal Women With Calcium and Vitamin-D Supplementation - a Randomised Study

Acronym: OSTPRE-FPS

Important dates

Study start
2002
Primary completion
2007
Study completion
2007
First posted
Jan 14, 2008
Registry last updated
Jan 14, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.